Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2014

View Archived Issues

Phase II results for the influenza A/H7N9 vaccine in combination with an adjuvant

Shionogi recaps highlights of second quarter of fiscal 2014

Novel genetic biomarkers of human malformation disorders

Sumitomo Dainippon Pharma reviews second quarter of fiscal 2014

Sanofi presents highlights of third quarter 2014

Researchers present novel targets and biomarkers in pancreatic cancer

FDA orphan drug status granted to oprozomib for multiple myeloma

Sodium thiosulfate designated orphan drug by the FDA

Glioma candidate pritumumab receives U.S. orphan drug designation

MPDL-3280A well tolerated in phase Ia trial in patients with mRCC

EMA publishes revised guideline on biosimilars

EMA releases third and final module on influenza vaccine guidance for public consultation

Chugai licenses EpiVax de-immunization technologies to optimize biologics pipeline

Swiss approval to begin Ebola vaccine trial

Award supports Verona Pharma's exploration of RPL-554 for cystic fibrosis

New PDE4B inhibitors reported by Gruenenthal

Esteve presents novel ligands of sigma receptors

Guangzhou Baiyunshan Pharmaceutical synthesizes tricyclic quinolones

Canadian company presents CRP40 fragments for neurological disorders

Glenmark Pharmaceuticals reports novel mPGES-1 inhibitors

New GnRH receptor antagonists discovered at Bayer Schering Pharma

Salix and Pharming launch Ruconest in the U.S. for acute angioedema attacks in HAE

Novartis plans phase I/II trial of Wnt-targeting drug regimen in BRAF-mutant colorectal cancer

Arena Pharmaceuticals to test APD-811 in patients with pulmonary arterial hypertension

Nymox's NX-1207 fails to achieve efficacy endpoints in phase III BPH trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...